Provided by Tiger Trade Technology Pte. Ltd.

VanEck Pharmaceutical ETF

108.06
-0.0800-0.07%
Pre-market: 107.27-0.7922-0.73%04:00 EDT
Volume:272.52K
Turnover:29.38M
Market Cap:1.03B
PE:87.56
High:108.33
Open:108.14
Low:107.29
Close:108.14
52wk High:118.00
52wk Low:90.60
Shares:9.54M
Float Shares:9.54M
Volume Ratio:0.61
T/O Rate:2.86%
Dividend:2.14
Dividend Rate:1.98%
EPS(TTM):1.23
EPS(LYR):0.7765
ROE:--
ROA:--
PB:--
PE(LYR):139.17

Loading ...

Novartis to License Drug from China's Abogen in up to $7.8 Billion Deal

Dow Jones
·
Oct 02

Major Drugmakers Turn to China for Licensing Deals

Reuters
·
Oct 02

Sanofi, Regeneron's Dupixent Successors Might Fall Short of Rivals

Dow Jones
·
Oct 02

Novartis, Abogen Sign RNA Licensing Agreement Worth up to $7.2 Billion

MT Newswires Live
·
Oct 02

Novartis Strikes up to $7.8 Billion mRNA Deal with China's Abogen

Reuters
·
Oct 02

Merck & Co. Inc. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Oct 02

Sector Update: Healthcare

MT Newswires Live
·
Oct 02

AbbVie (ABBV) Stock May Be 41% Undervalued On FDA Approval

Simply Wall St.
·
Oct 02

Trump Medicare Drug Pricing Model May Apply to Only Four Companies After Exemptions

Reuters
·
Oct 02

Merck's Tulisokibart Data From Hidradenitis Suppurativa Trial Looks Solid, UBS Securities Says

MT Newswires Live
·
Oct 02

Eli Lilly's Obesity Data Support Broader Portfolio Beyond Tirzepatide, UBS Says

MT Newswires Live
·
Oct 02

Eli Lilly (LLY) Ends Cancer Development Deal with Foghorn Therapeutics

TIPRANKS
·
Oct 01

AbbVie Says Phase 3 Trials Show Rinvoq Vitiligo Repigmentation Gains Extend to Week 76

Reuters
·
Oct 01

Abbvie - Phase 3 Studies Show Continued Repigmentation with Rinvoq Through Week 76

THOMSON REUTERS
·
Oct 01

Abbvie - Rinvoq Plus NB-Uvb Shows Higher Repigmentation than Rinvoq Alone

THOMSON REUTERS
·
Oct 01

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (OtherSNYNF), Sagimet Biosciences, Inc. Class A (SGMT) and Eli Lilly & Co (LLY)

TIPRANKS
·
Oct 01

AbbVie to Host Third-Quarter 2026 Earnings Call Webcast

Reuters
·
Oct 01

Foghorn Therapeutics Slashes Jobs After Ending Cancer Drug Trials with Ely Lilly

Dow Jones
·
Oct 01

Jefferies Adjusts Price Target on Merck & Co to $177 From $175, Keeps Buy Rating

MT Newswires Live
·
Oct 01

InflaRx Appoints Gabriela Alperovich as SVP, Global Head of Clinical Development

Reuters
·
Oct 01